Clinical Trial Update: Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing interferon alfa-2b with or without thalidomide in patients with metastatic or unresectable kidney cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interferon alfa-2b (interferon alfa-2b)
• Thalomid (thalidomide)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Kidney Cancer | Phase 3 | Status: COMPLETED